Psychiatr. praxi. 2024;25(1):40-42 | DOI: 10.36290/psy.2024.005

A little known facts about pregabalin

MUDr. Lucie Bundárová
Klinika psychiatrie, Fakultní nemocnice Olomouc

Pregabalin is a structural analogue of γ-aminobutyric acid, originally developed as an anticonvulsant. However, it has shown a number of other desirable effects and since 2016 is registered and indicated in psychiatry in the Czech Republic for the treatment of generalized anxiety disorder. Pregabalin is undoubtedly an effective and well-functioning drug, but it presents risks that should be considered in daily clinical practice. It's addictive and abusive potential is coming to the fore in both research and practice, which, as in the case of a number of previous substances, was discovered mainly by specific risk groups of patients and subsequently by their doctors. The article aims to introduce the reader to this lesser-known face of pregabalin. The summary is then supplemented with case studies by the author, who deals with the issue within her addiction practice and, above all, within her practice as a prison psychiatrist.

Keywords: pregabalin, addiction, abuse, addictology.

Accepted: March 25, 2024; Published: March 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bundárová L. A little known facts about pregabalin. Psychiatr. praxi. 2024;25(1):40-42. doi: 10.36290/psy.2024.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kavoussi R. Pregabalin: from molecule to medicine. European Neuropsychopharmacology. 2006;16:S128-S133. Go to original source... Go to PubMed...
    2. Schjerning O, Rosenzweig M, Pottegård A, et al. Abuse potential of pregabalin: a systematic review. CNS drugs. 2016;30:9-25. Go to original source... Go to PubMed...
    3. Roth T, Arnold LM, Garcia-Borreguero D, et al. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep medicine reviews. 2014;18(3): 261-271. https://doi.org/10.1016/j.smrv.2013.07.005 Go to original source... Go to PubMed...
    4. Slíva J. Pregabalin v léčbě generalizované úzkostné poruchy. Čes a slov Psychiatr. 2019;115(5):229-231.
    5. Ehler E. Farmakologický profil pregabalinu (Lyrica). Neurol. Praxi. 2014;15(6):350-354.
    6. Rojíčková MJ. Využití pregabalinu v klinické praxi. Neurol. Praxi. 2016;17(5):320-322. Go to original source...
    7. Kasper S, Iglesias-García C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. International Journal of Neuropsychopharmacology. 2014;17(5):685-695. Go to original source... Go to PubMed...
    8. Zaccara G, Gangemi P, Perucca P, et al. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826-836. Go to original source... Go to PubMed...
    9. Zellner N, Eyer F, Zellner T. Alarming pregabalin abuse in Munich: prevalence, patterns of use and complications. Deutsche Medizinische Wochenschrift. 2017;142(19):e140-e147. Go to original source... Go to PubMed...
    10. Prášil V, Prášilová M. Pregabalin jako zneužívaná substance: kazuistiky léčby závislosti. Psychiatr. Praxi. 2023;24(2):109-111. Go to original source...
    11. Chebli A. Literature review on pregabalin and the risk of addiction. Toxicologie Analytique et Clinique. 2022;34(3):S101. Go to original source...
    12. Evoy KE, Sadrameli S, Contreras J, et al. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81:125-156. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.